Alex Wilkes Is Appointed President, Americas of CooperVision

Alex Wilkes appointment becomes effective June 14.

Alex Wilkes brings more than a decade of experience in the eye care industry, having most recently served as Senior Vice President and General Manager of Pearle Vision at Luxottica.

At CooperVision, Wilkes will be responsible for the executive leadership and driving the growth of the company’s largest region, determining the strategic direction for the United States, Canada, and Latin America.

“In the years Alex has spent in vision care, he has led the expansion of one of the largest franchises in the industry, working directly with eye care professionals to build their businesses while playing a key role in branding, marketing, operations, product strategy, and supply chain management,” said Mark Harty, Executive Vice President and Chief Commercial Officer, CooperVision. “Alex’s proven track record of driving growth, developing market-shifting strategies, and leading high-performing teams is sure to benefit CooperVision and our customers in the years ahead.”

“The current pace of change in the optical category is unprecedented, and I’m thrilled to join the talented team at CooperVision to deliver some of the most innovative products in the market to eye care professionals and their patients,” said Wilkes. “I have admired CooperVision for many years and I am completely aligned with the values and direction of the company.”

Wilkes joined Luxottica in 2010 as Senior Director of Strategy and Business Development, where he was responsible for the strategic planning and implementation of several growth initiatives for LensCrafters. In 2012, he was promoted to the Vice President of Vision Care for LensCrafters. As part of the executive leadership team, he had responsibility for 3,000 eye care professionals, all clinical services, and the company’s contact lens portfolio.

Prior to that, Wilkes was a management consultant at Accenture for more than five years, with a focus on the consumer products, retail, and telecommunications industries. Earlier in his career, he was a consultant at Deloitte. Wilkes earned his bachelor’s degree from the University of Iowa. He will be based at CooperVision’s offices in Victor, N.Y.

Wilkes succeeds Jerry Warner, who was promoted to President of CooperVision in February 2022.


Other executives on the move and in the news can be found here.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”